An evaluation of intrathecal ziconotide for the treatment of chronic pain

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2403-2410

  Jain, K K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Antinociceptive; Cancer pain; Chronic pain; Intrathecal drug delivery; Ion channel blocker; N type calcium channels; Neuropathic pain; Omega conotoxin; Opioids; Post operative pain; SNX 111; Spasticity; Synchromed pump; Tolerance; Voltage specific calcium channels; Ziconotide

Indexed keywords

ALFENTANIL; BACLOFEN; BUPIVACAINE; BUPRENORPHINE; BUTORPHANOL; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; FENTANYL; HYDROMORPHONE; KETAMINE; LIDOCAINE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OMEGA CONOTOXIN MVIIA; PETHIDINE; PLACEBO; SUFENTANIL; TETRACAINE;

AGITATION; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; BRADYCARDIA; CHRONIC PAIN; CLINICAL TRIAL; COMA; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERANCE; DYSMETRIA; HALLUCINATION; HUMAN; HYPEREMIA; IN VITRO STUDY; IN VIVO STUDY; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MUSCLE SPINDLE AFFERENT NERVE; NAUSEA; NERVOUS TISSUE; NEUROTRANSMITTER RELEASE; NONHUMAN; NYSTAGMUS; ORTHOSTATIC HYPERTENSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; RAT; RISK BENEFIT ANALYSIS; SEDATION; URINE RETENTION; VERTIGO; VOMITING;

EID: 0033810234     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2403     Document Type: Article

References (31)

1. Pain therapeutics: Need for re-evaluation of strategies
2. A guide to the evaluation of drugs for the management of pain
3. Conotoxins
4. Sodium structure of w-conotoxin MVIIA using 2D NMR spectroscopy
5. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels
6. Pharmacotherapeutic potential of omega-conotoxin MVIIA, an N-type neuronal calcium channel blocker found in the venom of Conus Magus
7. Neuronal calcium channel antagonists: Discrimination between calcium channel subtypes using w-conotoxin from Conus magnus venom
8. Irreversible and reversible blockade of IMR32 calcium channel currents by synthetic MVIIA and iodinated MVIIC omega-conopeptides
9. Calcium channel antagonist peptides define several components of transmitter release in the hippocampus
10. A novel omega-conopeptide for the presynaptic localization of calcium channels at the mammalian neuromuscular junction
11. Voltage-sensitive calcium channels in spinal nociceptive processing: Blockade of N- and P-type channels inhibits formalin-induced nociception
12. Selective N-type neuronal voltage sensitive calcium channel blocker, SNX-111, produced spinal anti-nociception in rate model of acute, persistent neuropathic pain
13. SNX-111. Antinociceptive agent. N-type voltage-sensitive calcium channel blocker
14. Effect of subcutaneous administration of calcium channel blockers on nerve injury-induced hyperalgesia
15. Synthetic omega-cocopeptides applied to the site of nerve injury suppress neuropathic pains in rats
16. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats
17. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain
18. Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat
19. Pharmacokinetics of SNX-111, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys
20. Bioavailability of ziconotide in brain: Influx from blood, stability, and diffusion
21. Clinical data on SNX-111: Early results indicate exciting potential
22. Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain
23. SNX-111 in the treatment of Neuropathic Pain caused by AIDS: Early results promising
24. Initial results for clinical studies of SNX-111 for the treatment of pain
25. Neurex completes ziconotide phase III malignant pain trial.: Preliminary results support NDA filing
26. International Association for the Study of Pain (Part IV)
27. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain
28. Ziconotide for the treatment of severe spasticity after spinal cord injury
29. Cardiovascular effects of omega-conopeptides in conscious rats: Mechanisms of action
30. A double blind, placebo controlled safety and tolerability study of SNX-111
31. Adverse effects associated with the intrathecal administration of ziconotide